The Effect of Time to Postoperative Radiation Therapy on Survival in Resected Merkel Cell Carcinoma.


Journal

American journal of clinical oncology
ISSN: 1537-453X
Titre abrégé: Am J Clin Oncol
Pays: United States
ID NLM: 8207754

Informations de publication

Date de publication:
08 2019
Historique:
pubmed: 28 6 2019
medline: 10 3 2020
entrez: 28 6 2019
Statut: ppublish

Résumé

Delays from surgery to adjuvant radiation therapy (aRT) are associated with poorer prognosis in multiple neoplasms. Presently, no data exist for Merkel cell carcinoma (MCC). The authors sought to assess the time interval from surgery to aRT and effect on outcomes in MCC. The National Cancer Database was queried for histologically confirmed nonmetastatic MCC status post resection and aRT diagnosed between 2004 and 2015 who received aRT within 24 weeks of surgery. Kaplan-Meier analysis assessed univariate overall survival (OS); multivariable Cox proportional hazards modeling assessed multivariate OS; χ and logistic regression assessed differences in baseline characteristics and predictors of delayed aRT. Of 5952 patients meeting criteria, 13% commenced aRT within 4 weeks, 48% between 4 and 7 weeks, 23% between 8 and 11 weeks, 11% between 12 and 15 weeks, and 6% between 16 and 24 weeks. There were no differences in OS on the basis of the surgery-aRT interval (P=0.99). Predictors of worse OS on the multivariate analysis included advanced age, greater comorbidities, male sex, lower regional income, earlier year of diagnosis, more advanced tumor and nodal staging, positive margins, head and neck location, and treatment at community facilities (P<0.05 for all). Factors predictive of delayed aRT were identified. Subset analyses on these factors, such as receipt of chemotherapy or positive lymph nodes, did not demonstrate that the timing of aRT affected survival (P≥0.37). This study of a contemporary national database revealed that delays from resection to aRT were not associated with survival in MCC, somewhat discordant from other malignancies such as squamous cell carcinoma.

Identifiants

pubmed: 31246585
doi: 10.1097/COC.0000000000000565
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

636-642

Auteurs

Ashwin Shinde (A)

Departments of Radiation Oncology.

Vivek Verma (V)

Department of Radiation Oncology, Allegheny General Hospital, Pittsburgh, PA.

Bernard L Jones (BL)

Department of Radiation Oncology, University of Colorado, Aurora, CO.

Richard Li (R)

Departments of Radiation Oncology.

Scott Glaser (S)

Departments of Radiation Oncology.

Morganna Freeman (M)

Medical Oncology.

Laleh Melstrom (L)

Surgery, City of Hope National Medical Center, Duarte, CA.

Robert Kang (R)

Surgery, City of Hope National Medical Center, Duarte, CA.

Upendra Parvathaneni (U)

Department of Radiation Oncology, University of Washington, Seattle, WA.

Badri Modi (B)

Surgery, City of Hope National Medical Center, Duarte, CA.

Arya Amini (A)

Departments of Radiation Oncology.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH